Top

Archives of Gynecology and Obstetrics

Published in:

01-11-2018 | Gynecologic Oncology

Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer

Authors: Yilin Wang, Lili Zhang, Xiaoxia Che, Wenzhi Li, Zhiming Liu, Jie Jiang

Published in: Archives of Gynecology and Obstetrics | Issue 5/2018

Abstract

Purpose

The prevalence of endometrial cancer (EC) is increasing worldwide. Progestin therapy is effective for both early stage EC patients who require preserving fertility and advanced or recurrent patients. Progestin resistance resulting from downregulation of progesterone receptor (PR) remains a major problem, and its mechanism is currently unclear. It was demonstrated that Sirtuin 1 (SIRT1), forkhead transcription factor 1 (FoxO1) and sterol regulatory element binding protein-1 (SREBP-1) may act as a pathway and play crucial roles in the development of EC in our previous studies. In the present study, we investigated the effect on the development of progestin resistance and the relationship with PR of SIRT1/FoxO1/SREBP-1.

Methods

A progestin-resistant Ishikawa cell line was established in the stimulation and selection of medroxyprogesterone acetate (MPA), and the resistance was analyzed by MTT assay, flow cytometry, and Transwell invasion assay. qRT-PCR and western blotting were conducted to detect the expression of SIRT1, FoxO1, SREBP-1 and PR. SIRT1 knockdown progestin-resistant cells were established by lentiviral transduction.

Results

The new progestin-resistant cell line presented sufficient resistance to MPA in aspects of proliferation, distribution of cell cycle and apoptosis compared with original Ishikawa cells. Besides, the invasion capability of progestin-resistant cells was observably increased. In both protein and mRNA levels, SIRT1 and SREBP-1 were upregulated in progestin-resistant cells, while PR and FoxO1 were downregulated. SIRT1 was knocked down by lentivirus transfection in progestin-resistant cells, resulting in upregulation of PR, FoxO1 and downregulation of SREBP-1, thereby SIRT1 knockdown cells were more sensitive to MPA compared with progestin-resistant cells.

Conclusion

SIRT1/FoxO1/SREBP-1 act as a pathway targeting PR and involve in the development of progestin resistance in Ishikawa cells.

Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387(10023):1094–1108CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 67(1):7–30CrossRefPubMed

Jadoul P, Donnez J (2003) Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 80:1315–1324CrossRefPubMed

Li Q, Kannan A, DeMayo FJ et al (2011) The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science 331(6019):912–916CrossRefPubMedCentralPubMed

Banno K, Kisu I, Yanokura M et al (2012) Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (Review). Int J Oncol 40(6):1755–1762PubMed

Gunderson CC, Fader AN, Carson KA, Bristow RE (2012) Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 125:477–482CrossRefPubMed

Brunet A, Sweeney LB, Sturgill JF et al (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 303(5666):2011–2015CrossRefPubMed

Fang YJ, Nicholl MB (2011) Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett 306(1):10–14CrossRefPubMed

Lin L, Zheng X, Qiu C, Dongol S, Lv Q, Jiang J, Kong B, Wang C (2014) SIRT1 promotes endometrial tumor growth by targeting SREBP-1 and lipogenesis. Oncol Rep 32(6):2831–2835CrossRefPubMed

10.

Tzivion G, Dobson M, Ramakrishnan G (2011) FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813(11):1938–1945CrossRefPubMed

11.

Paik JH, Kollipara R, Chu G et al (2007) FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128(2):309–323CrossRefPubMedCentralPubMed

12.

Zhang Y, Zhang L, Sun H, Lv Q, Qiu C, Che X, Liu Z, Jiang J (2017) Forkhead transcription factor 1 inhibits endometrial cancer cell proliferation via sterol regulatory element-binding protein 1. Oncol Lett 13(2):731–737CrossRefPubMed

13.

Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, Moffat J, WranaJ L, Schimmer AD (2011) Inhibition of SREBP-1 sensitizes cells to death ligands. Oncotarget 2(3):186–196CrossRefPubMedCentralPubMed

14.

Li W, Tai Y, Zhou J et al (2012) Repression of endometrial tumor growth by targeting SREBP-1 and lipogenesis. Cell Cycle 11:2348–2358CrossRefPubMedCentralPubMed

15.

Chakrabarti P, English T, Karki S, Qiang L, Tao R, Kim J, Luo Z, Farmer SR, Kandror KV (2011) SIRT1 controls lipolysis in adipocytes via FOXO1-mediated expression of ATGL. J Lipid Res 52(9):1693–1701CrossRefPubMedCentralPubMed

16.

Deng X, Zhang W, Osullivan I, Williams JB, Dong Q, Park EA, Raghow R, Unterman TG, Elam MB (2012) FoxO1 inhibits sterol regulatory element-binding protein-1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. J Biol Chem 287(24):20132–20143CrossRefPubMedCentralPubMed

17.

Park JY, Nam JH (2015) Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist 20(3):270–278CrossRefPubMedCentralPubMed

18.

Park JY, Kim DY, Kim TJ (2013) Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol 122(1):7–14CrossRefPubMed

19.

Park JY, Lee SH, Seong SJ (2012) Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 129(1):7–11CrossRefPubMed

20.

Zhao S, Li G, Yang L, Li L, Li H (2013) Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate. Oncol Lett. 5(1):139–144CrossRefPubMed

21.

Yang S, Thiel KW, Leslie KK (2011) Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 22:145–152CrossRefPubMedCentralPubMed

22.

Qiu C, Dongol S, Lv Q, Gao X, Jiang J (2013) Sterol regulatory element-binding protein-1/fatty acid synthase involvement in proliferation inhibition and apoptosis promotion induced by progesterone in endometrial cancer. Int J Gynecol Cancer 23:1629–1634CrossRefPubMed

23.

Wang G, Fu Y, Xu W, Feng Y, Fang S, Zhou X (2009) Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 380(3):644–649CrossRefPubMed

Title: Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer
Authors: Yilin Wang
Lili Zhang
Xiaoxia Che
Wenzhi Li
Zhiming Liu
Jie Jiang
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 5/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-4893-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2018

Is an obstetrician/gynecologist a worker, artist, or scholar? Anxiety of an old professor

Termination of pregnancy following prenatally diagnosed central nervous system malformations

A prospective cohort study on the prediction of the diagnosis-to-delivery time in preeclamptic pregnancies: should the sFlt-1/PlGF ratio be added to routine evaluations?

Therapeutic role of granulocyte colony-stimulating factor (G-CSF) for infertile women under in vitro fertilization and embryo transfer (IVF-ET) treatment: a meta-analysis

Secondary cytoreduction in ovarian cancer: who really benefits?

Acute genital ulcers: keep Lipschütz ulcer in mind